Co-occurring post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) is the most common response to trauma; it is associated with poor clinical outcomes and substantial human disability.
Veterans with both PTSD and MDD (PTSD+MDD) have been shown to be at much greater suicidal risk than individuals with only one of these disorders. Ketamine given as repeated infusions has been shown to be effective in rapidly reducing PTSD and MDD symptoms in treatment resistant PTSD+MDD individuals. However, knowledge about the mechanisms underlying comorbid PTSD and MDD remain limited.
The purpose of this study is to use repeated ketamine infusions as a probe to validate a model of PTSD+MDD that focuses on neuroanatomy and executive functioning.
Trial Details
Trial Number
Sponsors & Collaborators
University of New MexicoThis company doesn't have a full profile yet, it is linked to a clinical trial.
Heffter Research Institute
The Heffter Research Institute has been advancing psychedelics (psilocybin) as medicines since 1993.
Measures Used
Montgomery-Asberg Depression Rating ScaleA ten-item diagnostic questionnaire used to measure the severity of depressive symptoms in patients with mood disorders.
PTSD Symptom Scale Interview for DSM-5
The PTSD Symptom Scale Interview for DSM-5 (PSS-I-5) is a 24-item semi-structured interview that assesses PTSD symptoms in the past month and makes a diagnostic determination based upon DSM-5 criteria. Respondents with a known trauma history identify a single traumatic event that causes the most current distress. Each of the 24-items is assessed with a single question with no follow-up questions. Symptom items are then rated on a five-point scale of frequency and severity ranging from 0 (not at all) to 4 (6 or more times/week).